Incretin Atlas·MoleculesTrialsOutcomesTimelinePipelineAboutMedical Adviser's Group
Incretin Atlas › Trials › FLOW

FLOW

Semaglutide · CKD + T2D, T2D + CKD

Data cut 12 November 2026 · page built 16 November 2026

Design

Molecule(s)
Semaglutide
Population
CKD + T2D, T2D + CKD
Official title
A Research Study to See How Semaglutide Works Compared to Placebo in People With Type 2 Diabetes and Chronic Kidney Disease
Sponsor
Novo Nordisk A/S
Phase
Phase 3
Registry status
completed · 2019-06 → 2024-01
Participants
3533
Duration
178 weeks
Registry
NCT03819153

Cardiovascular and kidney outcomes

FLOW semaglutide 1.0 mg vs placebo · T2D + CKD · n = 3533 · 2024 verified

EndpointHR95 % CIEvents, drug vs controlStatus
3-point MACE
Major cardiovascular events: nonfatal MI, nonfatal stroke, or CV death (confirmatory secondary outcome, time to first event)
0.820.68–0.98212 vs 254verified
Cardiovascular death
Death from cardiovascular causes (includes undetermined causes adjudicated by the committee)
0.710.56–0.89123 vs 169verified
All-cause death
Death from any cause (confirmatory secondary outcome)
0.800.67–0.95227 vs 279verified
Myocardial infarction
Nonfatal myocardial infarction only (fatal MI not separately reported)
0.800.55–1.1552 vs 64verified
Stroke
Nonfatal stroke only (fatal stroke not separately reported)
1.220.84–1.7763 vs 51verified
Major kidney disease events primary
Major kidney disease events: kidney failure (long-term dialysis, transplantation, or sustained eGFR <15), sustained ≥50% eGFR reduction from baseline, or death
0.760.66–0.88331 vs 410verified
Sustained eGFR decline (≥50 %)
Persistent >=50% reduction from baseline in eGFR (component of primary outcome; persistent = two consecutive measurements >=4 weeks apart)
0.730.59–0.89165 vs 213verified
Kidney failure (eGFR <15)
Persistent eGFR <15 ml/min/1.73 m2 (component of primary outcome)
0.800.61–1.0692 vs 110verified
Kidney failure (kidney-replacement therapy)
Initiation of kidney-replacement therapy (dialysis or transplantation; component of primary outcome)
0.840.63–1.1287 vs 100verified
Major adverse limb events
Major adverse limb event, time-to-first-event analysis
0.560.30–1.0216 vs 28verified
Verbatim quotes (10)
  • 3-point MACE · Results, Confirmatory Secondary Outcomes; Table 2; Figure 1E
    The risk of major cardiovascular events was 18% lower in the semaglutide group than in the placebo group (212 vs. 254 events; hazard ratio, 0.82; 95% CI, 0.68 to 0.98; P = 0.029)
  • Cardiovascular death · Table 2; Figure 1C
    Death from cardiovascular causes 123 (7.0) 169 (9.6) 0.71 (0.56 to 0.89)
  • All-cause death · Results, Confirmatory Secondary Outcomes; Table 2; Figure 1F
    The risk of death from any cause was 20% lower in the semaglutide group than in the placebo group (227 vs. 279 events; hazard ratio, 0.80; 95% CI, 0.67 to 0.95, P = 0.01)
  • Myocardial infarction · Table 2
    Nonfatal myocardial infarction 52 (2.9) 64 (3.6) 0.80 (0.55 to 1.15)
  • Stroke · Table 2
    Nonfatal stroke 63 (3.6) 51 (2.9) 1.22 (0.84 to 1.77)
  • Major kidney disease events · Results, Primary Outcome; Table 2; Figure 1A
    331 first events [5.8 per 100 patient-years of follow-up] vs. 410 first events [7.5 per 100 patient-years]), ... hazard ratio, 0.76; 95% confidence interval [CI], 0.66 to 0.88; P = 0.0003
  • Sustained eGFR decline (≥50 %) · Table 2, components of primary outcome
    Persistent ≥50% reduction from baseline in eGFR 165 (9.3) 213 (12.1) 0.73 (0.59 to 0.89)
  • Kidney failure (eGFR <15) · Table 2, components of primary outcome
    Persistent eGFR <15 ml/min/1.73 m2 92 (5.2) 110 (6.2) 0.80 (0.61 to 1.06)
  • Kidney failure (kidney-replacement therapy) · Table 2, components of primary outcome
    Initiation of kidney-replacement therapy 87 (4.9) 100 (5.7) 0.84 (0.63 to 1.12)
  • Major adverse limb events · Table 2 (continued), lower section
    Major adverse limb event in a time-to-first-event analysis — no. of events 16 28 0.56 (0.30 to 1.02)

Outcomes in the indication

FLOW Semaglutide · CKD + T2D · 178 weeks · n = 3533 seed

Major kidney events HR 0.76; all-cause death HR 0.80

MeasureDrugControlDifference (95 % CI)Status
Major kidney disease events (kidney failure, >=50% eGFR reduction, kidney or CV death)
week 177
+331.0+410.0+0.8 (+0.7 to +0.9) hazard ratioverified
Verbatim quotes (1)
  • Major kidney disease events (kidney failure, >=50% eGFR reduction, kidney or CV death)
    The risk of a primary-outcome event was 24% lower in the semaglutide group than in the placebo group (331 vs. 410 first events; hazard ratio, 0.76; 95% confidence interval [CI], 0.66 to 0.88; P = 0.0003)

Primary sources

How to cite this page

Medical Adviser's Group. Incretin Atlas: FLOW. Data cut 12 November 2026. https://docs.mdwrt.app/infographics/incretin-atlas/trials/flow/ Data: doi:10.5281/zenodo.23473913. Accessed 16 November 2026.

Cite the primary publication for any single result; every value above links to it.